Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Emre Altıntas"'
Autor:
Kadir Bocu, Ali Furkan Batur, Zeliha Esin Celik, Murat Gül, Emre Altıntas, Mehmet Kaynar, Ozcan Kılıç, Murat Akand, Sumeyye Nur Tataroglu, Serdar Goktas
Publikováno v:
Urologic Oncology: Seminars and Original Investigations.
Autor:
Serdar Göktaş, Murat Celik, Halil Özer, Murat Gül, Ali Furkan Batur, Özcan Kılıç, Mehmet Kaynar, Emre Altıntaş
Publikováno v:
Genel Tıp Dergisi, Vol 33, Iss 5, Pp 576-581 (2023)
Aims: To compare the post-radical prostatectomy (RP) final pathologies and post-biopsy pathologies of the patients diagnosed with prostate cancer (PCa) after fusion biopsy according to the International Society of Urological Pathology (ISUP) grading
Externí odkaz:
https://doaj.org/article/02be6726f36b48aa97c27538d2bd5ced
Autor:
Murat Gül, Mehmet Gökhan Çulha, Kadir Bocu, Ali Furkan Batur, Emre Altıntaş, Mehmet Kaynar, Serdar Göktaş, Özcan Kılıç
Publikováno v:
Journal of Urological Surgery, Vol 9, Iss 2, Pp 82-89 (2022)
Objective:As the evidence has been increasing about the post-micturition dribble (PMD) symptom, widely accepted lower-urinary tract symptoms (LUTS) questionnaires fail to assess PMD alone. In this study, our primary aim was to evaluate the validity a
Externí odkaz:
https://doaj.org/article/2a295c21198d4890a1dc55cf5dc5cfb6
Autor:
Ali Furkan Batur, Mustafa Gülmen, Kadir Böcü, Emre Altıntaş, Murat Gül, Mehmet Kaynar, Özcan Kılıç, Serdar Göktaş
Publikováno v:
Genel Tıp Dergisi, Vol 31, Iss 4, Pp 396-401 (2021)
Amaç Bu çalışmada böbrek taşı tedavisi için kliniğimizde retrograt intrarenal cerrahi(RİRC) uygulanılan geriatrik yaş grubu erkek hastaların etkinlik ve güvenlik sonuçlarının, daha genç yaş hasta grubu ile karşılaştırılarak su
Externí odkaz:
https://doaj.org/article/d3033169de544ce5acfda8f46d242fec
Autor:
Sabin Goktas Aydin, Engin Eren Kavak, Atakan Topcu, Ayberk Bayramgil, Fahri Akgul, Seda Kahraman, Musa Baris Aykan, Yunus Emre Altıntas, Kaan Helvaci, Yuksel Urun, Ahmet Bilici, Mesut Seker, Mehmet Ali Nahit Sendur, Omer Fatih Olmez, Ozgur Acikgoz, Irfan Cicin
Publikováno v:
Biomolecules & Biomedicine, Vol 23, Iss 6 (2023)
Regorafenib, an oral multikinase inhibitor, has improved survival in metastatic colorectal cancer (mCRC) patients who have progressed on standard therapies. Our study aimed to evaluate prognostic factors influencing regorafenib treatment and assess t
Externí odkaz:
https://doaj.org/article/307cb5703f46446fb0e16815e2f38f8b